Evidence map›Paper›PMID 42094601›Full record

ArticleTheranostics2026

Integrated radio-theranostics using a [

Yongkang Qiu, Tingfei Gu, Tianyao Wang, Yelin Mulati, Xinyao Sun, Qi Yang, Lele Song, Tingting Yuan, Yu Fan, Lei Kang and 1 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07774533 (Clinical Evaluation of a 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Patients With Osteosarcoma), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07774533 early_phase1recruitingnot on this map

Clinical Evaluation of a 68Ga-Labeled B7-H3 Nanobody for ImmunoPET Imaging in Patients With Osteosarcoma

TypeinterventionalSponsorPeking University First HospitalRan2026 to 2026Enrolled16ConditionsOsteosarcoma, Osteosarcoma, Recurrent, RefractoryArms68Ga-B7-H3 Nanobody PET/CT
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Development and Preclinical Evaluation ofJournal of medicinal chemistry · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yongkang QiuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Tingfei GuDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Tianyao WangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Yelin MulatiDepartment of Urology, Institute of Urology, Peking University First Hospital, Peking University, The National Urological Cancer Center of China, Beijing 100034, China.
Xinyao SunDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Qi YangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Lele SongDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Tingting YuanDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Yu FanDepartment of Urology, Institute of Urology, Peking University First Hospital, Peking University, The National Urological Cancer Center of China, Beijing 100034, China.
Lei KangDepartment of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.
Weibo CaiDepartments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Prostate cancer remains a leading cause of cancer-related mortality in men. Although PSMA-directed theranostics have achieved clinical success, heterogeneous expression and therapy-induced downregulation limit their broad applicability. B7-H3 (CD276), which is highly and stably expressed in prostate cancer, represents a promising alternative theranostic target. Methods: A B7-H3 targeted antibody-drug conjugate (ADC) was radiolabeled with [ Results: Histological analysis in prostate cancer patients suggested B7-H3 was consistently and highly expressed in primary and metastatic lesions and remained stable under therapeutic intervention. [ Conclusions: The [

Indexed as

B7 AntigensImmunoconjugatesLutetiumProstatic NeoplasmsRadioisotopesZirconiumAnimalsCell Line, TumorHumansMaleMiceTheranostic NanomedicineTissue DistributionXenograft Model Antitumor AssaysB7 AntigensCD276 protein, humanImmunoconjugatesLutetiumLutetium-177RadioisotopesZirconiumZirconium-89Antibody-drug conjugateB7-H3Prostate cancerRadioligand therapyTheranostics

Identifiers

PMID42094601
PMCPMC13142242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.